Literature DB >> 26315382

TP53 dysfunction in diffuse large B-cell lymphoma.

Ting-Xun Lu1, Ken H Young2, Wei Xu3, Jian-Yong Li4.   

Abstract

The aberrations of TP53 gene and dysregulation of the TP53 pathway are important in the pathogenesis of many human cancers, including malignant lymphomas, especially for diffuse large B cell lymphoma (DLBCL). By regulating many downstream target genes or molecules, TP53 governs major defenses against tumor growth and promotes cellular DNA repair, apoptosis, autophagy, cell cycle arrest, signaling, transcription, immune or inflammatory responses and metabolism. Dysfunction of TP53, including microRNA regulations, copy number alterations of TP53 pathway and TP53 itself, dysregulation of TP53 regulators, and somatic mutations by abnormal TP53 function modes, play an important role in lymphoma generation, progression and invasion. The role of TP53 in DLBCL has been widely explored recently. In this review, we summarized recent advances on different mechanisms of TP53 in DLBCL and new therapeutic approaches to overcome TP53 inactivation.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Copy number alterations; MDM2; Mutation; TP53; miRNA

Mesh:

Substances:

Year:  2015        PMID: 26315382     DOI: 10.1016/j.critrevonc.2015.08.006

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  13 in total

Review 1.  Diffuse large B-cell lymphoma: R-CHOP failure-what to do?

Authors:  Bertrand Coiffier; Clémentine Sarkozy
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

2.  CUL4B regulates autophagy via JNK signaling in diffuse large B-cell lymphoma.

Authors:  Ying Li; Xiangxiang Zhou; Ya Zhang; Juan Yang; Yangyang Xu; Yi Zhao; Xin Wang
Journal:  Cell Cycle       Date:  2019-02-01       Impact factor: 4.534

Review 3.  High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.

Authors:  Edward Nabrinsky; Alexey V Danilov; Paul B Koller
Journal:  Curr Hematol Malig Rep       Date:  2021-01-28       Impact factor: 3.952

4.  Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation.

Authors:  Glenda Nicioli da Silva; Leandro Toshio Filoni; Maria Cecília Salvadori; Daisy Maria Fávero Salvadori
Journal:  Pathol Oncol Res       Date:  2017-06-02       Impact factor: 3.201

5.  Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma.

Authors:  Sharvil P Patel; R Andrew Harkins; Michelle J Lee; Christopher R Flowers; Jean L Koff
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-12-24

6.  [Relationship between p53 rs1625895 polymorphism and prognosis in diffuse large B-cell lymphoma].

Authors:  Y Tian; J Zhu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-10-18

7.  TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.

Authors:  Helga D Munch-Petersen; Fazila Asmar; Konstantinos Dimopoulos; Aušrinė Areškevičiūtė; Peter Brown; Mia Seremet Girkov; Anja Pedersen; Lene D Sjö; Steffen Heegaard; Helle Broholm; Lasse S Kristensen; Elisabeth Ralfkiaer; Kirsten Grønbæk
Journal:  Acta Neuropathol Commun       Date:  2016-04-22       Impact factor: 7.801

8.  The feedback loop of LITAF and BCL6 is involved in regulating apoptosis in B cell non-Hodgkin's-lymphoma.

Authors:  Yaoyao Shi; Yue Kuai; Lizhen Lei; Yuanyuan Weng; Friederike Berberich-Siebelt; Xinxia Zhang; Jinjie Wang; Yuan Zhou; Xin Jiang; Guoping Ren; Hongyang Pan; Zhengrong Mao; Ren Zhou
Journal:  Oncotarget       Date:  2016-11-22

Review 9.  Smoldering mantle cell lymphoma.

Authors:  Haige Ye; Aakash Desai; Dongfeng Zeng; Krystle Nomie; Jorge Romaguera; Makhdum Ahmed; Michael L Wang
Journal:  J Exp Clin Cancer Res       Date:  2017-12-15

10.  Revealing the Mechanism of Astragali Radix against Cancer-Related Fatigue by Network Pharmacology and Molecular Docking.

Authors:  Yi Xie; Kainan Zhou; Yan Wang; Shuhan Yang; Suying Liu; Xueqian Wang; Ying Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-08       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.